This work leads us to explore the potential role of two endogenous molecules involved in the process of vascular stiffness (MMP-9 and TIMP1) present in the mechanisms of development and control of Resistant Hypertension. From this perspective, these molecules may, in the future, serve as clinical biomarkers for assessing the development of this condition as well as constituting a therapeutic target in the context of pharmacological treatment.